These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7365741)

  • 1. Synthetic modulators of the complement system. 1. Synthesis and biological activity of 5,5',5''-[1,3,6-naphthalenetriyltris(sulfonylimino)]-tris[1,3-benzenedisulfonic acid] hexasodium salt.
    Conrow RB; Bauman N; Brockman JA; Bernstein S
    J Med Chem; 1980 Mar; 23(3):240-2. PubMed ID: 7365741
    [No Abstract]   [Full Text] [Related]  

  • 2. Suppression of vascular injury at the Arthus reaction site by a complement inhibitor, 5,5',5''-(1,3,6-naphthalene-triyl-tris[sulfonylimino])-tris (1,3-benzene disulfonic acid) hexasodium salt.
    Abdel Mawla MY; Dingemans KP; Amer M; Venneker GT; van Meegen M; Asghar SS
    Complement Inflamm; 1991; 8(1):50-9. PubMed ID: 1828755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anticomplement function of heparin].
    Huang SW
    Sheng Li Ke Xue Jin Zhan; 1984 Oct; 15(4):360-3. PubMed ID: 6544523
    [No Abstract]   [Full Text] [Related]  

  • 4. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--I. Effect on fluid phase C1 and on C1 bound to EA or to EAC4.
    Raepple E; Hill HU; Loos M
    Immunochemistry; 1976 Mar; 13(3):251-5. PubMed ID: 1278930
    [No Abstract]   [Full Text] [Related]  

  • 5. Syntheses and complement inhibitory activities of 4-(2-phenyl-1H-indol-3-yl)cyclohexane-1-carboxylic acids.
    Bailey DM; DeGrazia GD; Alexander EJ; Powles RG; Johnson RE; Patrick RA; Heerdt BG; Fairbain ME; Pruden DJ
    J Med Chem; 1985 Feb; 28(2):160-4. PubMed ID: 3155799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-mediated alternative complement pathway activation resists inhibition by sialoglycolipids.
    Okada N; Yasuda T; Okada H
    J Immunol; 1985 May; 134(5):3316-9. PubMed ID: 2580023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of nafamstat mesilate (FUT175) on hyperacute rejection in discordant cardiac xenograft (guinea pig to rat): preliminary report].
    Fukushima N; Shirakura R; Nakata S; Ito T; Miyagawa S; Matsumiya G; Matsuda H
    Nihon Geka Gakkai Zasshi; 1992 Feb; 93(2):218. PubMed ID: 1552896
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis of low molecular weight compounds with complement inhibition activity.
    Master HE; Khan SI; Poojari KA
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1249-51. PubMed ID: 12657256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for different requirements in physical state for the interaction of lipopolysaccharides with the classical and alternative pathways of complement.
    Wilson ME; Morrison DC
    Eur J Biochem; 1982 Nov; 128(1):137-41. PubMed ID: 6756918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement.
    Ling M; Piddlesden SJ; Morgan BP
    Clin Exp Immunol; 1995 Dec; 102(3):582-8. PubMed ID: 8536376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic polyglycerol sulfates as new heparin analogues and potent inhibitors of the complement system.
    Türk H; Haag R; Alban S
    Bioconjug Chem; 2004; 15(1):162-7. PubMed ID: 14733596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [C1-inactivator from guinea pig serum-mechanism of action. I. Effect of the inactivator on C1 in free solution].
    Loos M; Opferkuch W; Wagner H
    Z Med Mikrobiol Immunol; 1971; 156(2):208-20. PubMed ID: 4995250
    [No Abstract]   [Full Text] [Related]  

  • 13. [C1-inactivator from guinea pig-serum mechanism of action. II. Effect of the inactivator on C1 in its bound form: EAC1, EAC14b and EAC14b2a].
    Loos M
    Z Med Mikrobiol Immunol; 1971; 156(2):221-32. PubMed ID: 5554814
    [No Abstract]   [Full Text] [Related]  

  • 14. Irreversible enzyme inhibitors. Inhibitors of guinea pig complement derived by quaternization of substituted pyridines with benzyl halides.
    Doll MH; Baker BR
    J Med Chem; 1976 Sep; 19(9):1079-88. PubMed ID: 978671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The influence of carrageenan, colchicine, 2,4-dinitrophenol, ethanol, galactose, indomethacin and liquoid on hemolytic complement activity (CH50E)].
    Stelzner A; Schleef H
    Allerg Immunol (Leipz); 1986; 32(2):129-33. PubMed ID: 3014848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A new C3NeF assay with zymosan-treated guinea-pig serum].
    Ohmori F; Ohi H; Seki M; Watanabe S; Hatano M
    Nihon Jinzo Gakkai Shi; 1986 Oct; 28(10):1423-7. PubMed ID: 3820819
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibitory effects of newly synthesized active center-directed trypsin-like serine protease inhibitors on the complement system.
    Ueda N; Midorikawa A; Ino Y; Oda M; Nakamura K; Suzuki S; Kurumi M
    Inflamm Res; 2000 Jan; 49(1):42-6. PubMed ID: 10778920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and evaluation of A/C/D-ring analogs of the fungal metabolite K-76 as potential complement inhibitors.
    Kaufman TS; Srivastava RP; Sindelar RD; Scesney SM; Marsh HC
    J Med Chem; 1995 Apr; 38(9):1437-45. PubMed ID: 7739002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure-activity study of protease inhibitors. V. Chemical modification of 6-amidino-2-naphthyl 4-guanidinobenzoate.
    Nakayama T; Taira S; Ikeda M; Ashizawa H; Oda M; Arakawa K; Fujii S
    Chem Pharm Bull (Tokyo); 1993 Jan; 41(1):117-25. PubMed ID: 8448813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The C1-inactivator of guinea pig serum: titration, purification and characterization of the inactivator].
    Opferkuch W; Loos M; Ringelmann R
    Z Med Mikrobiol Immunol; 1971; 156(2):194-207. PubMed ID: 4995249
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.